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Introduction: Although classic sensitizing mutations of epidermal 
growth factor receptor (EGFR) are positive predictive markers for 
EGFR tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma, 
there are rare EGFR mutations with unknown epidemiology and 
influence on prognosis and TKI response.
Methods: Eight hundred and fourteen lung adenocarcinoma patients 
with KRAS and/or EGFR mutation analyses for TKI therapy indi-
cation were identified. Six hundred and forty-five patients were 
included in the epidemiological analysis. The clinical outcome was 
analyzed in 419 advanced-stage patients with follow-up data.
Results: Four hundred and eighty (59%) KRAS/EGFR double wild-
type, 216 (27%) KRAS mutant, 42 (5%) classic, 49 (6%) rare, and 
27 (3%) synonymous EGFR mutant cases were identified. Twenty 
previously unpublished non-synonymous mutations were found. 
Rare EGFR mutations were significantly associated with smoking 
(vs. classic EGFR mutations; p = 0.0062). Classic EGFR mutations 
but not rare ones were independent predictors of increased overall 
survival (hazard ratios, 0.45; 95% confidence intervals, 0.25–0.82; 
p = 0.009). TKI therapy response rate of patients harboring classic 
EGFR mutations was significantly higher (vs. rare EGFR mutations; 
71% vs. 37%; p = 0.039). Patients with classic or sensitizing rare 
(G719x and L861Q) EGFR mutations had significantly longer pro-
gression-free survival when compared with the remaining rare muta-
tion cases (12 vs. 6.2 months; p = 0.048).
Conclusions: The majority of rare EGFR mutations was associated 
with smoking, shorter overall survival, and decreased TKI response 
when compared with classic EGFR mutations. However, studies 
characterizing the TKI sensitizing effect of individual rare mutations 
are indispensable to prevent the exclusion of patients with sensitiz-
ing rare EGFR mutations who may benefit from anti-EGFR therapy.
Key Words: Advanced-stage lung adenocarcinoma, Tyrosine kinase 
inhibitor therapy, EGFR mutation, Epidemiology.
(J Thorac Oncol. 2015;10: 738–746)
Lung cancer is the most frequently diagnosed malignancy worldwide and is a leading cause of mortality.1 The term 
lung cancer represents a rather heterogeneous group of dis-
eases including conditions of varying etiology and molecu-
lar background.2 Nevertheless, the determination of “driver” 
oncogenic mutations that play a decisive role in tumor devel-
opment can help to identify targets for therapy. In lung ade-
nocarcinoma, oncogenic mutations of the epidermal growth 
factor receptor (EGFR) are the most frequent biologically 
targetable alterations. To date, most of the anti-EGFR drugs 
introduced are tyrosine kinase inhibitors (TKIs), and the 
classic mutations of L858R and exon 19 microdeletions can 
serve as positive predictive biomarkers for response to these 
agents.3 However, there are other EGFR mutations responsible 
for primary or acquired resistance against TKI therapy.4,5 In 
addition, many rare EGFR mutations (in our report defined 
as all nucleotide changes resulting in amino acid sequence 
change in the tyrosine kinase coding region [exon 18–21] 
of EGFR excluding exon 19 microdeletions and the L858R 
point mutation in exon 21) have been described with unknown 
clinical relevance.6–11 Synonymous (silent) EGFR mutations 
are defined as nucleotide changes without amino acid change 
in the EGFR protein.12 EGFR mutations occur almost exclu-
sively in adenocarcinomas; their incidence, however, greatly 
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varies in different populations, showing the highest frequency 
among East-Asian nonsmoker women.13,14
The presence of KRAS mutation is a negative predictive 
factor for anti-EGFR therapy.15,16 Massive clinical data also accu-
mulated showing that KRAS and EGFR mutations are mutu-
ally exclusive (with rare exceptions).17 Accordingly, in Hungary, 
KRAS testing is performed first to exclude KRAS mutant 
cases from EGFR analysis to optimize testing efficiency.18 This 
approach enabled us to compare EGFR mutant, KRAS mutant, 
and EGFR/KRAS double wild-type (WT) patient cohorts.
In advanced lung adenocarcinoma, the clinical signifi-
cance of rare EGFR mutations has not yet been clearly estab-
lished.8,19 Therefore, we analyzed one of the largest cohorts of 
Caucasian patients with known KRAS and EGFR mutational 
status to compare the epidemiology and clinical consequence 
of rare and classic EGFR mutations.
PATIENTS AND METHODS
Study Population
In this retrospective analysis, 814 consecutive Caucasian 
patients with pathologically confirmed lung adenocarcinomas 
and treated at the National Koranyi Institute of Pulmonology, 
Budapest, Hungary or at the Department of Pulmonology, 
Semmelweis University, Budapest between January 2010 and 
March 2013 were included (Fig. 1). All patients underwent 
EGFR and/or KRAS mutation tests required for potential anti-
EGFR therapy. All tumor samples were obtained before TKI 
treatment. Major clinicopathological characteristics including 
performance status, smoking history, and tumor stage could 
be collected for 645 patients, and their correlations with muta-
tional status were analyzed for epidemiological purpose. The 
full clinical follow-up—including overall survival (OS)—was 
collected for 419 unresected, advanced-stage patients. In this 
subcohort, 64 EGFR-mutant cases with full clinical follow-
up were studied. Tumor, node, metastasis stage was evalu-
ated according to the Union for International Cancer Control 
(seventh edition)20 at diagnosis. Patients were divided into 
“never-smokers” (smoked less than 100 cigarettes during their 
lives), “former smokers” (smoked more than 100 cigarettes 
but had not smoked for at least a year), and “current smok-
ers.” Smoking status, Eastern Cooperative Oncology Group 
performance status (ECOG PS), and age were evaluated at 
the time of diagnosis. Institutional tumor boards in line with 
FIGURE 1.  Patient cohort and mutational analysis flow chart (n = 814 patients).
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lung cancer therapy guidelines of the participating centers 
did not allow the use of TKIs in patients with ECOG PS > 2. 
Accordingly, only patients with initial ECOG PS 0–2 were 
included into the EGFR mutation analysis.
Mutation Analysis
All mutational analyses were performed at the Second 
Department of Pathology or at the First Department of 
Pathology and Experimental Cancer Research, Semmelweis 
University as previously described.18,21 Briefly, regions of 
tumor samples embedded in paraffin blocks containing the 
highest concentrations of tumor cells were macrodissected.18 
DNA was extracted using the MasterPure DNA Purification 
Kit according to the manufacturer’s instructions. KRAS muta-
tions were identified by microcapillary-based restriction frag-
ment length analysis as described previously.18,21 Polymerase 
chain reaction amplification of the EGFR exons 18, 19, and 
21 in 143 cases (24%) and exons 18, 19, 20, and 21 in 459 
patients (76%) was the first step, followed by bidirectional 
Sanger sequencing. Sensitivity of this methodology is approx-
imately 20% (it is able to detect mutations in specimens with 
at least 20% cancer cell content); its specificity is nearly 
100%.22 In seven cases, the TheraScreen: EGFR29 Mutation 
Kit (DxS Ltd., UK) was used. This technique has a sensitivity 
of approximately 1% and a specificity of 100%.22
Treatment and Response Evaluation
Retrospective clinical data and treatment history were 
available in the advanced-stage cohort (unresected stages IIIA 
and IIIB–IV) for 419 lung adenocarcinoma patients. Drug 
administration was performed according to the Hungarian 
health care financial regulations for TKI therapy. From January 
2010, erlotinib (in second or third line) could be given to 
advanced lung adenocarcinoma patients with a KRAS WT 
tumor (orally at a daily dose of 150 mg in second and/or third 
line). First line gefitinib (orally at a daily dose of 250 mg) 
became available from March 2012 for patients with an activat-
ing EGFR mutation. Thirty-three and 118 patients received gefi-
tinib and erlotinib as monotherapy, respectively. The study and 
all treatments were conducted in accordance with the current 
National Comprehensive Cancer Network guidelines, based on 
the ethical standards prescribed by the Helsinki Declaration of 
the World Medical Association and with the approval of the 
national level ethics committee that included a waiver for this 
retrospective study (52614-4/2013/EKU). According to the 
national treatment financing scheme, all EGFR TKI-treated 
patients had to return to the hospital every month for review. 
The therapeutic efficacy of anti-EGFR TKIs was assessed from 
contrast-enhanced computed tomography before treatment ini-
tiation and then every 3 months. Therapy response was catego-
rized by Response Evaluation Criteria in Solid Tumors 1.1 as 
stable disease (SD), partial or complete response, or progres-
sive disease. Response rate (RR) was calculated as the number 
of patients with complete response or partial response divided 
by the number of patients in a given group. OS was estimated 
from the time of diagnosis in patients presenting with unresect-
able advanced-stage disease until death or last available fol-
low-up. Progression-free survival (PFS) was calculated from 
the date of initiation of the TKI treatment to the date of detec-
tion of progressive disease or death.
Statistical Methods
Categorical parameters of the different mutational 
groups were analyzed by χ2 test. Age as a continuous variable 
was analyzed in the mutational groups by analysis of variance 
and Tukey’s multiple comparison test. Kaplan–Meier curves 
and two-sided log-rank tests were used for univariate survival 
analyses. Cox proportional hazards model was used for uni-
variate and multivariate survival analyses to calculate the haz-
ard ratios (HR) and corresponding 95% confidence intervals 
(CI). For multivariate survival analyses, the Cox regression 
model was adjusted for age (as a continuous variable), gen-
der (female vs. male), smoking status (never-smoker vs. ever-
smoker), ECOG PS (0 vs. 1–2), and stage (IIIA vs. IIIB-IV). 
The p values are two-sided and were considered significant 
below 0.05. Metric data are shown as median or mean and 
corresponding range, or, in case of OS and PFS, as median 
and corresponding 95% CI. All statistical analyses were per-
formed using the PASW Statistics 18.0 package (SPSS Inc., 
Chicago, IL).
RESULTS
Epidemiology of EGFR and KRAS 
Mutations in Lung Adenocarcinoma
Five hundred and eighty patients of the full cohort 
of 814 cases were identified as KRAS WT (71%) and 216 
(27%) as KRAS mutant (in 18 cases [2%], no KRAS muta-
tion analysis was performed, Fig. 1). There were 42 (5%) 
classic EGFR mutant (four patients with concomitant KRAS 
mutation), 49 (6%) rare EGFR mutant (non-classic mutation 
where amino acid change occurs; including three patients 
with concomitant KRAS mutation), and 27 (3%) patients 
with synonymous (silent) EGFR mutations (non-classic 
mutations without amino acid change in EGFR; including 
nine patients with concomitant KRAS mutation), and 480 
(59%) of the cases was classified as KRAS/EGFR double 
WT (Fig. 2A). Of note, in five patients, the G719x or L861Q 
rare sensitizing mutation was identified.23 All rare and 
synonymous EGFR mutations are listed in Supplemental 
Table 1 (Supplemental Digital Content 1, http://links.lww.
com/JTO/A803). On the basis of the COSMIC database 
(retrieved at July 28, 2014), we found synonymous and rare 
EGFR gene mutations already published in lung cancer (N 
= 33 mutations) or in malignancies of other organs (N = 20 
mutations).24 In addition, 45 previously unpublished novel 
mutations were identified. The T790M mutation was not 
detected in any patients. Interestingly, in 16 patients, we 
identified a complex mutation pattern, with at least two dif-
ferent EGFR mutations found within a single sample (total 
of 39 mutations identified for the 16 patients).
The major clinicopathological characteristics could be 
collected for 645 patients and are presented for the various 
mutational statuses in Supplemental Table 2 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A803). Significant 
association of gender and mutational status was not detected 
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(Fig. 2B; p = 0.780). Patients with KRAS mutations were sig-
nificantly younger than those with classic EGFR mutations or 
with EGFR/KRAS double WT tumors (Fig. 2C; p = 0.0002). 
Classic EGFR mutation was significantly associated with 
never-smoker status when compared with all other mutational 
statuses (Fig. 2D; p < 0.0001). Rare EGFR mutations were 
found to be associated with smoking (vs. classic EGFR muta-
tions; Fig. 2D; p = 0.0062).
Distinct Effect of Classic Versus Rare 
EGFR Mutations on Overall Survival 
in Lung Adenocarcinoma
Clinical follow-up including OS could be collected in 
the advanced-stage cohort (unresected stages IIIA and IIIB–
IV) for 419 patients (Table 1). Gender, age, ECOG PS, disease 
stage, smoking status, and mutational status were tested for 
predicting OS. Male patients had significantly shorter OS (vs. 
females; HR, 1.32; 95% CI, 1.04–1.66; p = 0.0195). Patients 
with ECOG PS 0 had significantly better OS than those pre-
senting with ECOG PS 1–2 (HR, 2.07; 95% CI, 1.63–2.62; 
p < 0.0001; Fig. 3A). Patients with stage IIIB or IV tumors 
had significantly shorter OS than those with unresected stage 
IIIA (HR, 0.637; 95% CI, 0.478–0.850; p = 0.002; Fig. 3B). 
We found no difference in OS between stages IIIB and IV 
patients (data not shown). Furthermore, we found signifi-
cantly increased OS among never-smokers when compared 
with ever-smoker patients (HR, 0.666; 95% CI, 0.497–0.892; 
p = 0.0063; Fig. 3C). Classic EGFR mutation conferred a sig-
nificant benefit for OS when compared with WT (HR, 0.58; 
95% CI, 0.37–0.91; p = 0.02) or KRAS mutation (HR, 0.52; 
95% CI, 0.31–0.89; p = 0.0167). In contrast, there was no 
significant difference in the OS of rare EGFR mutation posi-
tive patients compared with patients with WT EGFR or with 
mutant KRAS. Of note, there was no effect of KRAS muta-
tional status on OS.
Multivariate survival analyses (Supplemental Table 3A, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A803) showed that—besides ECOG and stage—classic 
EGFR mutation was an independent survival predictor (HR, 
0.45; 95% CI, 0.25–0.82; p = 0.009). Importantly, rare EGFR 
mutation was not a significant independent predictor of OS 
(Supplemental Table 3B, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A803).
FIGURE 2.  Distribution and epidemiology of KRAS and EGFR mutations in lung adenocarcinoma patients. A, Mutational  
status in the full cohort (n = 814). B, There was no significant association between mutational status and gender. C, Patients  
with KRAS mutation were significantly younger than those with classic EGFR mutations or with EGFR/KRAS double WT tumors 
(p = 0.0002). D, In contrast to classic EGFR mutations, rare EGFR mutations were significantly associated with smoking (p = 0.0062). 
EGFR, epidermal growth factor receptor; WT, wild-type.
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Different Response to TKI Therapy in 
Advanced Lung Adenocarcinoma Patients 
with Classic Versus Rare EGFR Mutations
Next, we evaluated the therapy response and PFS of 
TKI-treated advanced lung adenocarcinoma patients with 
classic and rare EGFR mutations (Table 2 and Supplemental 
Table 4, Supplemental Digital Content 1, http://links.lww.
com/JTO/A803). Irrespective of treatment line, there was a 
significantly increased RR among patients with classic EGFR 
mutations compared with those with rare EGFR mutations 
TABLE 1.  Major Clinicopathological Characteristics of the Advanced-Stage Lung Adenocarcinoma Patient Cohort with Full 
Clinical Follow-up (n = 419)
Total
Classic EGFR 
Mutation
Rare EGFR 
Mutation
Synonymous 
EGFR Mutation KRAS mutation
KRAS and 
EGFR wild-type P value
Total 419a (100) 22c (5) 26d (6) 16c (4) 80b (20) 271a (65)
Age (mean ± SD) 63.9 ± 10.3 67.4 ± 10.4 63.5 ± 9.8 64.3 ± 8.80 59.9 ± 10.9 64.6 ± 9.8 0.003
Gender Male 203 (48) 7 (32) 13 (50) 7 (44) 37 (46) 135 (50) 0.571
Female 216 (52) 15 (68) 13 (50) 9 (56) 43 (54) 136 (50)
ECOG status 0 185 (45) 13 (59) 13 (50) 8 (50) 35 (44) 116 (45) 0.709
1–2 223 (55) 9 (41) 13 (50) 8 (50) 45 (56) 144 (55)
Unknown data 11 0 0 0 0 11
Smoking status Never-smoker 70 (17) 9 (43) 6 (23) 3 (19) 8 (10) 44 (17) 0.028
Former smoker 134 (33) 7 (33) 6 (23) 6 (37) 34 (43) 81 (32)
Current smoker 198 (50) 5 (24) 14 (54) 7 (44) 37 (47) 131 (51)
Unknown data 17 1 0 0 1 15
Tumor Stage Unresected IIIA 68 (16) 2 (9) 5 (19) 10 (63) 16 (20) 36 (13) <0.001
 IIIB–IV 351 (84) 20 (91) 21 (81) 6 (37) 64 (80) 235 (87)  
Data shown in parentheses are column percentages. Categorical parameters of the different mutational groups were analyzed by χ2. Age as a continuous variable was analysed in 
the mutational groups by analysis of variance and Tukey’s multiple comparison test.
a KRAS molecular analysis was not done in four cases.
b EGFR molecular analysis was not done in 54 cases.
c Two concomitant KRAS mutations were identified.
d Two concomitant KRAS mutations were identified, and KRAS analysis was not done in two cases.
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
FIGURE 3.  Kaplan–Meier curves for the OS of advanced lung adenocarcinoma patients (n = 419). A, ECOG PS 1–2 (vs. ECOG PS 0; 
p < 0.0001), (B) stages IIIB–IV (vs. stage IIIA; p = 0.002), and (C) smoking (vs. never-smoking; p = 0.006) were significant prognostic 
factors for reduced OS. D, Moreover, patients with tumors harboring classic EGFR mutations had a significantly better OS than those 
with EGFR/KRAS double WT (p = 0.02) or with KRAS mutant tumors (p = 0.002). Importantly, EGFR classic mutation was not associ-
ated with benefit in OS if these patients were compared with the rare EGFR mutant cohort (p = 0.529). OS, overall survival; ECOG 
PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; WT, wild-type.
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(RR 71% vs. 37%, respectively; p = 0.039, Supplemental 
Fig. 1A, Supplemental Digital Content 2, http://links.lww.
com/JTO/A804). This translated into a statistically not sig-
nificant but clinically notable longer PFS: the median PFS 
values were 12 and 6.2 months in the classic and rare EGFR 
mutation cohorts, respectively; (p = 0.076; Supplemental 
Fig. 1B, Supplemental Digital Content 2, http://links.lww.
com/JTO/A804). We found no significant difference in the 
OS in the above-mentioned subgroup of patients (p = 0.212; 
Supplemental Fig. 1C, Supplemental Digital Content 2, http://
links.lww.com/JTO/A804). Importantly, when classic EGFR 
mutation positive patients were pooled together with patients 
harboring TKI-sensitizing rare EGFR mutations (G719 and 
L861)23 and compared with the remaining rare mutation cases, 
the difference in RR remained significant (RR 70% vs. 36%, 
respectively; p = 0.044, Fig. 4A), and the effect on PFS reached 
statistical significance (p = 0.048; Fig. 4B). Importantly, there 
was a significant difference in the OS in the latter comparison 
(p = 0.01; Fig. 4C).
DISCUSSION
Precise definition of the tumor type, including compre-
hensive histological classification and description of clinically 
relevant molecular pathological characteristics, is crucial for 
precision or individualized (lung) cancer therapy.25 On the 
basis of the classic activating mutations of EGFR, a number of 
patients can now be successfully treated with selective EGFR 
TKIs. However, there are several rare mutations in the EGFR 
gene with unknown epidemiology and influence on TKI 
response. Importantly, the incidence of these mutations varies 
in different ethnic groups and is also influenced by environ-
mental factors and smoking habit.26 For this very reason, we 
compared the epidemiology and clinical consequence of clas-
sic and rare EGFR mutations in a Hungarian cohort of lung 
cancer patients.27
In the current study, 5% of patients carried classic 
EGFR mutation. In a very recent survey from Germany, the 
incidence of confirmed activating EGFR mutation among 
adenocarcinoma patients was reported to be 6%.27,28 The inci-
dence of rare nonsynonymous EGFR mutations in our cohort 
was 6% and therefore is higher than in similar Caucasian stud-
ies (1.9–2.7%)28,29 or in a mixed US study population (4%),9 
but similar to East-Asian studies where the incidence of rare 
mutations is ranging from 7% to 8%.7,23,30 The higher propor-
tion of rare mutations in our Caucasian cohort is likely due 
to the facts that exon 20 sequencing was also performed in 
FIGURE 4.  Anti-EGFR tyrosine kinase inhibitor treatment in advanced lung adenocarcinoma patients with confirmed sensitizing 
(classic EGFR mutations pooled together with patients with sensitizing rare EGFR mutations [G719x and L861Q]) versus all other 
rare EGFR mutations. A, Irrespective of treatment line, patients with sensitizing EGFR mutations responded significantly better to 
TKI therapy (data presented as number of patients; p = 0.047). Furthermore, these patients had significantly longer PFS (B) and 
OS (C) than those with other rare EGFR mutations (p = 0.043 and 0.01, respectively). EGFR, epidermal growth factor receptor; 
TKI, tyrosine kinase inhibitor; PFS, progression-free survival; OS, overall survival.
TABLE 2.  Distribution of EGFR Mutation Status in TKI-Treated Patients
TKI Therapy
Total First line Second and Third Line
Total 151 (100) 30 (20) 121 (80)
WT for KRAS and EGFR 98 0 98 (100)
Synonymous EGFR mutation 9 2 (22) 7 (78)
Non-synonymous EGFR mutation Total 44 28 (64) 16 (36)
Classic 24 17a (71) 7a (29)
 Rare 20 11b (55) 9 (45)
Data shown in parentheses are row percentages.
aIn one patient concomitant KRAS mutation was identified.
bIn two patients concomitant KRAS mutation was identified.
TKI, tyrosine kinase inhibitor; WT, wild-type; EGFR, epidermal growth factor receptor.
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76% of the patients and, moreover, that 40% of all KRAS 
mutant cases underwent EGFR analysis as well. Of note, in 
seven patients, concomitant KRAS and classic or rare EGFR 
mutations were identified in our study. These patients repre-
sent 0.9% (7 of 814) of the whole cohort and 1.2% (7 of 584) 
of the group of patients with both KRAS and EGFR muta-
tion analyses. This ratio is in line with previously published 
data.6,31 Of note, 2% of our patients carried complex mutation 
pattern (at least two different EGFR mutations in one sam-
ple), meanwhile an East-Asian study published 7.3%.7 To our 
knowledge, no Caucasian population-based study reported the 
incidence of complex EGFR mutations so far.
We did not detect the resistance associated T790M 
mutation in our patient cohort. This is in line with its very low 
incidence (0–0.9%) in previous studies in patients before TKI 
therapy using methods without increased sensitivity toward 
mutant alleles.32,33 In contrast, studies enriching for mutant 
alleles using a peptide-nucleic acid to inhibit the amplification 
of WT allele found much higher incidence of pretreatment 
T790M mutations (35–65%).34,35
Significant associations between gender and rare EGFR 
mutational status were not detected in our cohort in line with a 
very recent—and to date the only similar—Caucasian study.10 
We found no significant association either between age and 
rare EGFR mutations in accordance with previous reports 
from Asia or with a mixed US cohort studying only EGFR 
exon 20 insertions.9,23 According to our knowledge, our study 
is the first to compare the age among classic and rare EGFR 
mutants in a Caucasian cohort. In the current cohort, patients 
with classic EGFR mutations tended to be older (mean age: 
67 ± 9.6 years) than those with rare EGFR mutations (mean 
age, 64.2 ± 9.2 years) and, moreover, were significantly older 
than patients carrying KRAS mutations (mean age: 60 ± 10.4 
years). Accordingly, the above-mentioned recent German 
study also found an almost significant trend between patients 
with KRAS (mean age, 65.3 ± 9.8 years) and EGFR mutations 
(mean age, 70.3 ± 11.4 years).28
In our cohort, rare—in contrast to classic—EGFR muta-
tions appeared to be associated with smoking status. This is in 
line with a Greek study in which Pallis et al.29 demonstrated 
that among patients with rare mutations smokers are more 
frequent, albeit not significantly, when compared with never-
smokers: 20.8% versus 8%. In a mixed population study, 
among EGFR exon 20 insertion mutant patients the propor-
tion of smokers was higher than among classic EGFR mutant 
patients.9 In contrast, East-Asian data show that rare EGFR 
mutations together with complex rare mutations are associ-
ated with never-smoker status,7 and that uncommon mutations 
are higher among never-smokers.23
To our knowledge, this is the first Caucasian population-
based advanced-stage disease cohort with RRs for first-gener-
ation TKI-treated rare EGFR mutation positive patients. In our 
cohort, RRs were 71% and 37% among patients with classic 
and rare EGFR mutations, respectively. This finding is in accor-
dance with studies from East-Asia where RRs were found to 
be 74–75% and 28–48%, respectively.7,23 Interestingly, in the 
LUX-Lung 2 phase II trial of the second-generation covalent 
TKI inhibitor afatinib, similar results were found as well (RRs 
in classic and rare EGFR mutant cohorts were 66% and 39%, 
respectively).30 Of note, the 12-month median PFS among 
classic EGFR mutant patients in our cohort is rather similar 
to previously published data (9.4–11.9 months) from other 
studies.7,36,37 Patients in our cohort with rare EGFR mutations 
demonstrated a shorter median PFS of 6.2 months. This is 
comparable to the 5-month median PFS of rare EGFR mutant 
patients in a recent East-Asian study performed by Wu et al.23 
Importantly, when patients with classic EGFR mutations were 
pooled with patients with rare activating EGFR mutations 
(G719 and L861), and then this cohort was compared with 
the remaining rare mutation harboring population, the effect 
on PFS reached significance. Interestingly, a similar robust 
difference was found in the recently published LUX-Lung 2 
clinical trial.30 Of note, the RR and PFS in our patient cohort 
with rare EGFR mutations (PFS: 7.4 months; RR: 31%) are 
comparable to that of the cisplatin–pemetrexed combination 
arm in the LUX-Lung 2 clinical trial (PFS, 6.9 months; RR, 
23%), which is now considered the most effective chemother-
apy regimen in lung adenocarcinoma.38
Classic EGFR mutations were associated with a sig-
nificantly better median OS when compared with rare EGFR 
mutations (20.5 vs. 7.4 months) in the current study. This find-
ing is in line with the results of other studies (19.3–20 months) 
on classic EGFR mutation positive cohorts but differs in the 
case of rare mutations (9–17 months), possibly due to the dif-
ferent types and proportion of rare EGFR mutations.7,23,29
With regard to factors associated with OS in lung ade-
nocarcinoma, we confirmed the prognostic significance of 
gender, ECOG PS, smoking status, disease stage, and EGFR 
mutations similar to the findings of Johnson et al.39 In mul-
tivariate analysis of standard prognostic parameters, only 
ECOG PS 0 proved to be an independent prognostic factor 
associated with longer OS. Furthermore, in line with the study 
of Johnson et al.,39 the presence of classic EGFR mutations 
had a statistically significant effect. Similar to the majority of 
previous publications,15 we were not able to confirm the prog-
nostic effect of KRAS mutations.
Our study has several limitations. Despite the fact that 
the initial cohort was large—as expected—the final num-
ber of patients with classic or rare EGFR mutations was 
relatively small. Nevertheless, our cohort—one of the larg-
est in this setting—provided the opportunity to draw some 
conclusions that evidently need to be validated in additional 
studies. Because of the study’s retrospective nature, some 
of our results need to be confirmed in a prospective setting. 
Furthermore, it remains unclear whether classic EGFR muta-
tion itself confers a more benign behavior or the increased RR 
and median PFS of the classic mutant cohort translate to this 
better prognosis. An important potential confounding factor 
is smoking status as several studies have demonstrated that 
never-smokers have improved OS.40,41 In our cohort, we found 
a significant OS advantage for never-smokers. However, at 
the same time, classic EGFR mutations were significantly 
more frequent among never-smokers than rare EGFR muta-
tions. Thus, it is likely that this increased OS is owing to the 
overall better performance and the lack of smoking-related 
comorbidities.40–43
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Altogether, classic EGFR mutations were associated with 
never-smoker status, older age, longer OS, and increased TKI 
response when compared with rare EGFR mutations in this ret-
rospective study. Molecular methods focusing only on classic 
EGFR mutations may prevent a number of patients with certain 
rare mutations to benefit from anti-EGFR therapy. Our study 
suggests that the predictive and prognostic values of rare EGFR 
mutations with regard to TKI therapy need to be evaluated in 
wide multinational studies for each individual mutation to opti-
mize EGFR-targeted therapy in lung adenocarcinoma and, more-
over, to define optimal screening strategy that can significantly 
reduce the costs of treatment with expensive therapeutic agents.
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